Nigrostriatal dopaminergic depletion increases static orofacial allodynia

Wisam Dieb1,2,3*, Omar Ouachikh3, Sofia Alves3, Yves Boucher1,2, Franck Durif3,4 and Aziz Hafidi3*

Abstract

Background: This study investigated mesencephalic dopamine depletion effects on static mechanical allodynia (SMA) elicited by chronic constriction of the infraorbital nerve (CCI-IoN).

Methods: Dopamine depletion (6-OHDA administration into the medial forebrain bundle) effects on CCI-IoN-induced SMA were explored using behavioral (nocifensive behavior score upon non-noxious stimuli using von Frey filament), pharmacological (bromocriptine injections) and immunohistochemical (PKCγ and pERK1/2) techniques.

Results: The central dopamine depletion increased significantly the SMA score. Intraperitoneal and intracisternal injections of bromocriptine alleviated the allodynic behavior observed in both CCI-IoN and CCI-IoN + 6-OHDA animal groups. At the cellular level, dopamine depletion induced a significant increase in PKCγ expression in the medullary dorsal horn (MDH) in rat with CCI-IoN + 6-OHDA when compared to sham animals (CCI-IoN only). Similarly, after static non-noxious stimuli, the expression of pain marker proteins pERK1/2 within the MDH revealed significantly a higher number of positive cells in CCI-IoN + 6-OHDA rats when compared to the CCI-IoN group.

Conclusion: This study demonstrates that nigrostriatal dopamine depletion exacerbates the neuropathic pain resulting from CCI-IoN. This effect is probably due to an action through descending pain inhibitory systems which increased pain sensitization at the MDH level. It demonstrates also an analgesic effect elicited by D2R activation at the segmental level.

Keywords: Parkinson disease, Dopamine, Pain, Substantia nigra, Chronic constriction injury, Neuropathic pain, Infraorbitary nerve

Background

Painful traumatic trigeminal neuropathy (PTTN) following peripheral nerve trauma is a disabling condition clinically characterized by spontaneous and evoked pain mainly experienced as burning and/or shooting pain [1]. It results from dysfunctions of the somatosensory system [2] and remains a therapeutic challenge since the current treatment options are unsatisfactory [3]. The physiopathology of PTTN points to both peripheral mechanisms involving neuro-glio-immuno vascular alterations mediated by chemokines/cytokines release and central mechanisms involving both alterations of ascending pathways and descending controls [4–7].

Dopamine has been proposed as playing a key role in chronic orofacial pain [8]. Nigrostriatal dopamine depletion is associated with increased pain sensitivity and is implicated in pain in different pathologies such as Parkinson’s disease, restless leg syndrome, fibromyalgia, burning mouth syndrome and atypical facial pain [9–13]. Conversely, striatal administration of dopamine 2 receptor (D2R) agonists has an anti-nociceptive effect mediated by the rostroventromedial medulla (RVM) [14]. Similar results showed that striatal inhibition of nociceptive responses evoked in the trigeminal system [15–17] and chronic oro-facial pain conditions in humans were associated with the alteration of the nigrostriatal dopaminergic system [9, 10]. Recent reports showed that bilateral or unilateral nigrostriatal dopaminergic lesions induce dynamic and static mechanical allodynia in the oro-facial region [16, 18]. Since the effects of dopamine depletion on the development of PTTN have
not been explored, the present study aimed at investigating the effects of nigrostriatal lesions in animals with a peripheral nerve injury: chronic constriction injury of the Infra Orbital Nerve (chronic constriction of the infraorbital nerve: CCI-IoN) model [19]. This model has the advantage of using the trigeminal nerve for pain related studies [20]. Bilateral nigrostriatal chemical lesions were performed by stereotaxic injection of the 6-OHDA toxin into medial forebrain bundle (MFB) in rats with CCI-IoN. In these animals, pain behavior (nociceptive, mechanical allodynia), expression of PKCy ([protein involved in pain chronicity] [21, 22]) and pERK1/2 (proteins expressed upon noxious stimuli in the spinal/medullary dorsal horn [23, 24]) were assessed with or without dopamine receptor (DR) agonists [bromocriptine (D2R), SKF81297 (D1R)] treatments.

Methods

Animals

Adult male Sprague–Dawley rats (N = 112, 275-325 g) from Charles River (L’Arbresle, France) were maintained in a controlled environment (lights on 07:00–19:00, 22 °C) with ad libitum access to food and water. The experiments followed the ethical guidelines of the International Association for the Study of Pain, the European Community Council directive of 24 November 1986 (86/609/EEC) and the Animal Ethics Committee of the University of Auvergne.

6-OHDA lesion

After anesthesia (Ketamine 60 mg/kg, xylazine, 10 mg/kg), rats were placed in a stereotaxic frame (David Kopf Instrument, CA, USA) and the MFB were injected bilaterally with 6-OHDA (0.5 μL/min) dissolved in a vehicle solution (0.02 % ascorbate saline) at a concentration of 3 μg/μL (Sigma-Aldrich, France) in two deposits (2.25 and 2.85 μg, respectively) at the following coordinates: anterior (A) –4.0; lateral (L) ± 0.8; ventral (V) –8.0; tooth bar at +3.4 and A –4.4; L ± 1.2; V –7.8; tooth bar at –2.4 [25]. To preserve adrenergic neurons from 6-OHDA toxicity, animals received desipramine (25 mg/kg, i.p., Sigma-Aldrich, France) 30 min prior to the toxin injection; sham-lesioned rats received only the vehicle at the same coordinates.

CCI-IoN surgery

CCI-IoN was performed following an established surgical procedure [5, 19]. Briefly, animals were anesthetized using chloral hydrate (400 mg/kg i.p.) and an incision of approximately 1 cm long was made along the gingivobuccal margin, begun just proximal to the first upper molar. About 0.5 cm of the IoN was freed of adhering tissue and two ligatures (4–0 chromic guts) separated by a 1–2 mm interval were tied loosely around it using 4–0 chromic gut. The sham operation was identical except that the nerve was not ligated.

Behavioral testing and analysis

The rats were adapted to the observation field (24 × 35 × 18 cm) and for 30 min each day for 9 days prior to the beginning of behavioral testing. During this period, the experimenter reached into the cage to apply von Frey (2 g) stimulus on the animals’ faces. For each behavioral testing, the rats were placed in the observation field for a 30 min period. Stimulation was carried out when the rat was in a sniffing/no locomotion state: with four paws placed on the ground, neither moving nor freezing. The stimulus was applied every 3 min onto the vibrissal pad (IoN territory). Each series of stimulation consisted of 5 von Frey filament (2 g) applications every 5 s alternating on each side of the face. This stimulus is non-noxious.

Behavioral responses were quantified by a blind-experimenter according to the method of [19]: (1) detection, the rats turn heads toward stimulus; (2) withdrawal reaction (the rats turn head away); (3) escape/attack, the rats avoid further contact with the stimulus, or attack the filament; (4) asymmetric grooming, the rats display an uninterrupted series of at least three wash strokes directed at the stimulated area. An absence of response corresponded to a zero score. A mean score value was then calculated for each series of stimulations. All the rats were subjected to 13 sessions of behavioral testing at different time points: before surgery (day 1) and after surgery, on weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12.

Immunohistochemistry

A day after behavioral experiments, rats were deeply anesthetized with urethane (1.5 g/kg i.p.), the vibrissal pads were ipsilaterally stimulated for 2 min by a von Frey filament 2 g (60 stimuli delivered, 0.5 Hz), and three minutes later, the rats were perfused transcardially with warm (37 °C) heparinized saline (25 IU heparin/ml) followed by cold (10 °C) phosphate-buffered solution (0.1 M, pH 7.6) containing 4 % paraformaldehyde and 0.03 % picric acid. The brains were placed in 30 % sucrose and 0.05 % sodium azide solution overnight at 4 °C. Brainstem coronal sections (30 μm) were cut on a freezing microtome and collected in 0.05 M Tris-buffered saline (TBS).

Free-floating sections were placed in 1 % normal goat serum for 1 h before overnight incubation at room temperature in primary antibody solutions (mouse anti-pERK1/2 [1:1000, Cell Signaling Technologies], and rabbit anti-PKCy [1:4000, Sigma-Aldrich and Santa Cruz]. The corresponding secondary antibodies (1:400 for goat anti-mouse Cy3, 1:200 for goat anti-rabbit Cy2) were incubated at room temperature for 3 h. All antibodies were diluted in TBS containing 0.25 % bovine serum albumin and 0.3 % Triton X-100. The sections were finally rinsed in TBS, mounted onto gelatin-coated slides, dehydrated in alcohol, cleared in xylene, and cover-slipped with distyrene-plasticizer-xylene. The specificity of the
immunostaining was assessed by omitting primary antibodies, which resulted in the absence of signal.

Immunostaining was analyzed using a motorized Zeiss Axioplan 2 microscope equipped with a Hamamatsu C4742-95 digital camera driven by MetaMorph® 5.4 software. In each rat, image acquisition and fluorescent signal quantification were performed from 7 different sections, each taken at a given rostrocaudal plane within the MDH (from 0 to −2160 μm at 360 μm intervals). Brainstem sections were categorized according to their approximate rostrocaudal location from the MDH subnucleus interpolaris junction. pERK1/2 positive cells were counted and data were expressed as the sum of the total number of labeled cells from all sections analyzed in each animal [16]. PKCy staining was quantified as previously reported [16]. Briefly, PKCy staining was quantified within lamina IIi and the number of positive cells was counted in lamina III. Tyrosine hydroxylase (TH) immunolabelling was performed (anti-TH primary antibody; Millipore, France) as described above. The quantification procedure of the 6-OHDA lesion impact on the SNc was reported previously [25].

**Drugs and administration**

Two weeks after the 6-OHDA injection, the animals were briefly (<3 min) anesthetized with 2 % halothane using a mask and received for intracisternal administration bromocriptine (7 μg/kg dissolved in 5 μl vehicle; Sigma-Aldrich, France) or the vehicle alone (5 μl of 0.9 % saline) according to our previous results [25]. For i.p. injection we used bromocriptine (1 mg/kg) and SKF81297 (3 mg/kg dissolved in 0.9 % saline; Sigma-Aldrich, France) concentrations [25]. Following a recovery period (<2 min), the rats were placed in the observation field for 40-min period-test by a blind-experimenter.

**Statistical analysis**

The results are expressed as mean ± SD. Statistical analysis was performed using Student’s t-test, or a one-way analysis of variance (ANOVA) followed by a post hoc Student Newman-Keuls test or a one-way Repeated Measures (RM) ANOVA followed by a post hoc Student-Newman-Keuls test. The level of significance was set at P < 0.05.

**Results**

**Dopamine depletion in the substantia nigra**

As shown in our previous study [25], 6-OHDA injections resulted in a considerable decrease of TH staining in the SNc of CCI-IoN + 6-OHDA when compared to CCI-IoN + saline animals (Additional file 1: Figure S1A and B). Cell count revealed a significant (p < 0.001, ***)) decrease in TH positive cells (70 % neuronal loss) in SNc of CCI-IoN + 6-OHDA rats (Additional file 1: Figure S1C). The impact of unilateral or bilateral depletion mesencephalic midbrain depletion on SMA has been studied previously [18].

**Dopamine depletion increases static mechanical allodynia (SMA) resulting from CCI-IoN**

The time course of SMA appearance (Fig. 1), resulting from the CCI-IoN, was similar to our previous report [16].

![Fig. 1](image-url) Time course of static mechanical allodynia (SMA) in the ipsilateral side to the injury (CCI-IoN) of 6 animal groups (each n = 8): CCI-IoN and its sham; 6-OHDA and its sham; and 6-OHDA + CCI-IoN and its sham. CCI-IoN animals showed a significant increase in the nocifensive score at post-surgery week 2 when compared to CCI-IoN-sham. The SMA score reached its maximum around the 4th week post-surgery and decreased slowly through the post-surgery observation period until week 12. SMA occurred rapidly within 3–4 days after 6-OHDA injection. This related SMA stayed significant when compared to sham for 7 weeks after the lesion. The highest nocifensive score was observed in the 6-OHDA + CCI-IoN group in comparison to all other groups. Despite the slight decrease observed along the 12 weeks post-surgery, the SMA score in this group remained significantly increased compared to all other groups. * * * * Comparison between CCI-IoN + 6-OHDA and CCI-IoN and 6-OHDA. # Comparison between CCI-IoN and CCI-IoN sham. + Comparison between CCI-IoN + 6-OHDA and CCI-IoN + 6-OHDA sham. ☆ Comparison between 6-OHDA and 6-OHDA sham. The bars represent standard deviation. *P < 0.05; **P < 0.01,***p < 0.001.
Briefly, 1 week post-surgery, significant SMA score (CCI-IoN) was obtained when compared to sham and reached its highest score \( p < 0.001, **\) 3 weeks post-surgery. This SMA was significant during 12 weeks post-injury.

The time course of 6-OHDA induced SMA appearance was similar to our previous report \([7]\). The SMA appeared relatively earlier after 6-OHDA injection than after CCI-IoN (Fig. 1) and stayed significant in comparison to 6-OHDA-sham during the first 6 weeks after the 6-OHDA lesion.

The CCI-IoN + 6-OHDA rats showed the highest significant \( p < 0.001, **\) SMA score within the ipsilateral side (Fig. 1) to the CCI-IoN injury in comparison to all other animal groups. This score was highly significant along the experiment duration. Similar results were obtained in the contralateral side, although with lower scores (data not shown).

**Bromocriptine administration decreases the SMA**

Intraperitoneal administration of bromocriptine induced a significant, dose dependent (0.1 mg and 1 mg/Kg) decrease in pain scores in CCI-IoN group when compared to sham (Fig. 2a) and its effect lasted for 6 h. The highest dose induced the highest score decrease, \( P < 0.01, **\). As a positive control SKF8129 (DR1 agonist) was used. Its intraperitoneal administration induced a non-significant increase in the SMA score when compared to sham (saline-injected).

Intracisternal administration of bromocriptine (Fig. 2b) decreased significantly the SMA score when compared to the vehicle group. No significant difference in SMA scores was observed when bromocriptine was injected intracisternally 90 min after the ip administration of sulpiride (c). Error bars = standard deviation. *: comparison between bromo 1 mg/kg (IP) and vehicle. #: comparison between bromo 0.1 mg/kg (IP) and vehicle.
to sham (saline-injected). Bromocriptine effect lasted for 20 min.

Intraperitoneal administration of bromocriptine (Fig. 2c) induced a significant dose dependent decrease in SMA score in CCI-IoN + 6-OHDA lesioned group compared to that of sham. Its effect lasted for 6 h. SKF81297 administration increased the allodynic score, although this score was not significant when compared to sham. Intracisternal administration of Bromocriptine (Fig. 2d) decreased significantly the SMA score compared to that of sham (saline-injected rats) and its effect lasted for 30 min.

PKCγ expression in the medullary dorsal horn

The general pattern of PKCγ staining was similar in both CCI-IoN (Fig. 3a) and CCI-IoN + 6-OHDA (Fig. 3b) groups. PKCγ staining (Fig. 3c) was highly observed within lamina IIi and in scattered cells within lamina III [16, 22]. PKCγ staining intensity quantification in lamina IIi (Fig. 3d) was significantly higher in both ipsilateral (P > .001, **) and contralateral (P > .05, *) MDH sides of CCI-IoN + 6-OHDA when compared to CCI-IoN rats. There was no significant PKCγ staining difference between ipsi- and contralateral sides in lamina IIi. Cell count of PKCγ positive cells in lamina III (Fig. 3e) was significantly increased in CCI-IoN + 6-OHDA when compared to CCI-IoN groups. There was no significant cell count difference between ipsilateral and contralateral sides.

Increased pERK1/2 expression in the MDH by 6-OHDA

pERK1/2 staining was observed in cells located principally within superficial lamina I and II of the MDH (Fig. 4a-c). At higher magnification the pERK1/2 labeling was observed in cells located mostly in laminae I and IIo (Fig. 4c). Cell count of pERK1/2 positive cells was significantly (P < .01, **) higher in CCI-IoN + 6-OHDA (Fig. 4d) when compared to CCI-IoN injured rats in the ipsilateral side to the injury (stimulated side). There was no significant difference in the number of pERK1/2 cells between CCI-IoN and CCI-IoN + 6-OHDA in the contralateral side. However there was a significant (P > .01, **) cell count difference between ipsi- and contralateral sides in both groups.

PKCγ and pERK1/2 are distinct cell subtypes

pERK1/2 (Fig. 5a) and PKCγ (Fig. 5b) double labeling revealed no co-localization of these markers in both CCI-IoN and CCI-IoN + 6-OHDA MDH (Fig. 5c).

A summary illustration of the present results is presented in the following table (+low, +++high).
Discussion

The main results of this study are: 1) Mesencephalic dopamine depletion augmented significantly the pain caused by CCI-IoN. 2) Bromocriptine administrations (intraperitoneal and intracisternal) attenuated SMA in both CCI-IoN and CCI-IoN + 6-OHDA animals. 3) Central dopamine depletion increased significantly PKCγ and pERK1/2 expressions in the MDH of CCI-IoN + 6-OHDA when compared to CCI-IoN group.

This study shows a synergistic or additional effect of central dopamine depletion and CCI-IoN on SMA in orofacial territories. The dopamine depletion increased the SMA caused by CCI-IoN. This is in agreement with our previous studies demonstrating the induction of dynamic and static [16, 18] mechanical allodynia in the trigeminal system upon midbrain dopamine depletion. Bromocriptine attenuated CCI-IoN-related SMA in a dose dependent manner. These results highlights an MDH local action of bromocriptine by the activation of D2R since SKF81297 (D1R agonist) had no significant effect on pain behavior.

These data are in accordance with previous results showing a direct inhibition of superficial spinal dorsal horn neurons by activation of D2R [26, 27].

At the molecular level, central depletion of dopamine increased synergistically the pre-existing expressions of PKCγ and pERK1/2 within MDH. PKCγ is known to be a key molecule for the onset of pain chronicity [21]. Its expression increases after CCI-IoN confirming previous studies [22, 24, 28]. Our result suggests that the lesion of the dopaminergic nigrostriatal system increased the SMA by acting on PKCγ cells through descending pain inhibitory system. PKCγ cells are known to activate a secondary cell subtype within MDH superficial laminae which expressed pERK1/2 [28] and the specific PKCγ inhibition decreased both the number of pERK1/2 cells and the related neuropathic pain behavior [24]. This highlights the essential role of PKCγ cells in inducing allodynia. PKCγ cells constitute a revolving door that induces alldynia through peripheral (CCI-IoN) or central lesions (nigrostriatal system). Moreover, bromocriptine administration has been shown in the same neuropathic model to decrease PKCγ expression levels in the MDH [16], thus suggesting that dopamine might act directly on PKCγ cells either by direct inhibition or indirectly through D2Rs present at excitatory presynaptic site at the

|            | CCI-IoN | 6-OHDA | CCI-IoN + 6-OHDA |
|------------|---------|--------|------------------|
| SMA        | ++      | +      | +++              |
| PKCγ       | ++      | +      | +++              |
| pERK       | ++      | +      | +++              |

**Fig. 4** Expression of pERK1/2 in saline-CCI-IoN (a) and 6-OHDA-CCI-IoN animals (b-c). pERK1/2 positive cells were observed within superficial laminae of the MDH in both groups. At high magnification the pERK1/2 positive cells were observed mostly in laminae Iio and I as delimited (yellow dots) in the figure (c). Cell count (d) of pERK1/2 positive cells showed a significant increase (P < 0.01; **) in 6-OHDA vs saline injected animals (n = 5 each group) in the ipsilateral MDH and a non-significant increase in the contralateral side. A significant increase in the number of pERK1/2 positive cells was observed in the ipsilateral side of 6-OHDA injected animals compared to the contralateral side. Scale bar represents 100 μm in A-B and 40 μm in C.
level of PKCy cells. In support of the latter, D2Rs have been detected post-synaptically on second-order neurons [29].

The implication of basal ganglia, in the processing of noxious somatosensory information is well documented [30]. Activation of the dopaminergic nigrostriatal system leads to a general anti-nociceptive effect [31], while its alteration enhances sensitivity to noxious stimuli [32, 33]. The anti-nociceptive dopamine effect is achieved through D2R receptors [14, 16, 31, 33].

In agreement with these data, the use of bromocriptine in the present study demonstrated also the involvement of D2R receptor in the anti-nociceptive effect resulting from both central dopamine depletion and CCI-IoN.

To date no direct nigral projections to the MDH is documented. Therefore, the increase of SMA is probably due to the indirect modulation of the pain descending modulatory system through the periaqueductal grey matter (PAG) [34]. The administration of apomorphine (a dopamine receptor agonist) into the PAG promotes anti-nociception [35]. GABA-ergic projections from SNc, substantia nigra reticula, ventral tegmental area and amygdala to the PAG have been described [36, 37]. Dopamine depletion in these structures may decrease GABA transmission at PAG level, thereby increasing the influence of descending facilitatory pain pathways on the MDH through the RVM. The latter represents the final common pain modulatory system [34]. Stimulation of striatal D2R suppressed nociceptive neuropathic pain through RVM modulation and activation of D2R and 5-HT receptors at the dorsal spinal horn [14]. The mesolimbic and meso-cortical dopamine projections can also participate to the increase of pain caused by CCI-IoN since 6-OHDA injection has been demonstrated to induce dopaminergic cell degeneration in the VTA [16, 18, 33]. Alternatively the segmental action of bromocriptine (intracisternal injection) may act via dopaminergic descending pathway which arise from the hypothalamus region A11 [38]. Other brain structures which receive mesencephalic dopamine innervation could also modulate nociception at the MDH level [39].

Our data supported the implication of the mesencephalic dopamine system in the PD, orofacial (burning mouth syndrome, atypical facial pain) and other pain-related pathologies (restless leg, fibromyalgia) (9.10.11.12, 13). It is worth to note that in PD, patients experimented pain during the Off-period (absence of dopamine replacement therapy) which highlighted the general role for dopamine in pain process. Thus central dopamine may have a general inhibitory action on pain directly by dopaminergic projections to descending pain control or indirectly through dopamine projections to target nuclei and its depletion may causes a general pain increase.

Conclusion
In conclusion the present study demonstrated a synergic effect of CCI-IoN and central dopamine depletion in neuropathic pain. The nigrostriatal dopamine increased allodynic behavior through D2R at segmental PKCy. D2R agonists might be used as analgesic mechanism for trigeminal allodynia.

Additional file

Additional file 1: Figure S1. Tyrosine Hydroxylase (TH) immunostaining in saline + CCI-IoN (A) and 6-OHDA + CCI-IoN (B) animals (n = 8) revealed a drastic decrease in the staining intensity mainly observed in the substantia nigra pars compacta (SNc). The cell count (C) demonstrated a significant (p < 0.001, ****) decrease in TH positive cells in the SNc of 6-OHDA rats when compared to shams. Scale bar = 170 μm in A-B. Error bar = standard deviation in C. ***, p < 0.001.

Competing interests
The authors declare that they have no competing interests.
Authors’ contributions

WD done the experiments, participate to the writing and discussion of the manuscript. OO done the experiment and participate to the discussion of the manuscript. SA done the experiment. YB participate to the writing and the discussion of the manuscript. FD participate to the discussion of the manuscript. AH participate to the elaboration of the project, writing and the discussion of the paper. All authors read and approved the final manuscript.

Acknowledgement

This work was supported by funding from Auvergne University.

Author details

1. UFR Odontologie, Université Paris Diderot, Paris, France. 2. Centre de Psychiatrie et Neurosciences, INSERM U894, Paris, France. 3. Clermont Université, Université d’Auvergne, EA7280, Clermont-Ferrand, France. *CHU Clermont-Ferrand, Service de Neurologie, 63000 Clermont-Ferrand, France.

Received: 30 September 2015 Accepted: 12 February 2016
Published online: 17 February 2016

References

1. Benoliel R, Zadik Y, Elav E, Sharav Y (2012) Peripheral painful traumatic trigeminal neuropathy: clinical features in 91 cases and proposal of novel diagnostic criteria. J Orofac Pain 26:49–58
2. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice ASC, Treede RD (2011) A new definition of neuropathic pain. Pain 152:2204–2206
3. Haviv Y, Zadik Y, Sharav Y, Benoliel R (2014) Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment. J Oral Facial Pain Headache 28:52–60
4. Iwata K, Tsuboi Y, Shima A, Harada T, Ren K, Kanda K, Kitagawa J (2004) Central neuronal changes after nerve injury: neuroplastic influences of injury and aging. J Orofac Pain 18:293–298
5. Dieb W, Hafidi A (2013) Astrocytes are involved in trigeminal dynamic mechanical allodynia: potential role of D-serine. J Dent Res 92:808–813
6. Mor comb M, Castro A, Guo W, Zou S, Ren K, Wei F, Keller A, Dubner R (2013) Transition to persistent orofacial pain after nerve injury involves supraspinal serotonin mechanisms. J Neurosci 33:5152–5161
7. Dauvergne C, Molet J, Reaux-Le Goazigo A, Mauborgne A, Mélis-Pardanani S, Boucher Y, Poizot M (2014) Implication of the chemokine CCL2 in trigeminal nociceptive and traumatic neuropathic orofacial pain. Eur J Pain 18:360–375
8. Wood PB (2008) Role of central dopamine in pain and analgesia. Expert Rev Neurother 8:781–797
9. Hagelberg N, Forsell H, Aalto S, Rinne JO, Scheinin H, Taiminen T, Någren K, Jääskeläinen SK (2003) Striatal dopamine D1 and D2 receptors in atypical facial pain. Pain; 106: 43–48
10. Hagelberg N, Forsell H, Rinne JO, Scheinin H, Taiminen T, Någren K, Jääskeläinen SK (2003a) Altered dopamine D2 receptor binding in atypical facial pain. Pain; 106: 43–48
11. Hagelberg N, Forsell H, Rinne JO, Scheinin H, Taiminen T, Aalto S, Luotonen S, Någren K, Jääskeläinen SK (2003b) Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain; 101: 149–154
12. Cervenka S, Pälhagen SE, Comley RA, Panagiotidou G, Cselényi Z, Matthews JC, Lai FY, Hallidin C, Farde L (2006) Support for dopaminergic hypooxygenation in restless legs syndrome: a PET study on D2-receptor binding. Brain J Neurol 129:2017–2028
13. Vakkhardt P, Minar M, Singliarova H, Harsany J, Hanakova M, Martinova J, Benetin J (2015) Pain in Parkinson’s Disease: A Cross-Sectional Study of its Prevalence, Types, and Relationship to Depression and Quality of Life. PLoS ONE 10x0136541
14. Ansah OB, Leite-Almeida H, Wei H, Pertovaara A (2007) Striatal dopamine D2 receptors attenuate neuropathic hyperresponsivity in the rat. Exp Neurol 205:535–546
15. Belforte JE, Pazo JH (2005) Striatal inhibition of nociceptive responses evolved in trigeminal sensory neurons by tooth pulp stimulation. J Neurophysiol 93:1730–1741
16. Dieb W, Ouachikh O, Durif F, Hafidi A (2014) Lesion of the dopaminergic nigrostriatal pathway induces trigeminal dynamic mechanical allodynia. Brain Behav 4:368–380
17. Barceló AC, Fillipini B, Pazo JH (2010) Study of the neural basis of striatal modulation of the jaw-opening reflex. J Neural Transm 117:171–181
18. Dieb W, Ouachikh O, Durif F, Hafidi A (2015) Nigrostriatal dopaminergic depletion produces orofacial static mechanical allodynia. Eur J Pain 29:70–82
19. Vos BP, Strassman AM, Maciewicz RJ (1994) Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat’s infraorbital nerve. J Neurosci 14:2708–2723
20. Kernisant M, Gear RW, Jasmin L, Vit JP, Ohara PT (2008) Chronic constriction injury of the infraorbital nerve in the rat using modified syringe needle. J Neurosci Methods 172:43–47
21. Malmberg AB, Chen C, Tongeau S, Baaburn AI (1997) Preserved acute pain and reduced neuropathic pain in mice lacking P(K)C gamma. Science 279:279–283
22. Nakajima A, Tsuboi Y, Suzuki I, Honda K, Shinoda M, Kondo M, Matsuura S, Shibuta K, Yasuda M, Shimizu N, Iwata K (2011) PKC gamma in Vc and C1/C2 is involved in trigeminal neuropathic pain. J Dent Res 90:777–781
23. J RR, Baba H, Brenner GJ, Woolf CJ (1999) Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 2:1114–1119
24. Dieb W, Alvarez P, Hafidi A (2015) PKC-y-positive neurons gate light tactile inputs to pain pathway through pERK1/2 neuronal network in trigeminal neuropathic pain model. J Oral Facial Pain Headache 29:70–82
25. Ouachikh O, Dieb W, Durif F, Hafidi A (2013) Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area. Behav Brain Res 252: 24–31
26. Tamae A, Nakatsuka T, Koga K, Kató G, Furue H, Katayuchi T, Yoshimura M (2005) Direct inhibition of substantia gelatinosa neurons in the rat spinal cord by activation of dopamine D2-like receptors. J Physiol 568:243–253
27. Taniguchi W, Nakatsuka T, Miyazaki N, Yamada H, Takeda D, Fujita T, Kumamoto E, Yoshida M (2011) In vivo patch-clamp analysis of dopaminergic antinociceptive actions on substantia gelatinosa neurons in the spinal cord. Pain 152:95–105
28. Dieb W, Hafidi A (2015) Mechanism of GABA involvement in post-traumatic trigeminal neuropathic pain: activation of neuronal circuitry composed of PKCy interneurons and pERK1/2 expressing neurons. Eur J Pain 19:85–96
29. Bergerot A, Storer RJ, Godastry PJ (2007) Dopamine inhibits trigeminovascular transmission in the rat. Ann Neurol 61:251–262
30. Chudler EH, Dong WK (1995) The role of the basal ganglia in nociception and pain. Pain 60:33–48
31. Magnussen JE, Fisher K (2000) The involvement of dopamine in nociception: the role of D(1) and D(2) receptors in the dorsolateral striatum. Brain Res 855:260–266
32. Saed NE, Atwah SF, Bahouth NB, Jabbur SJ (1997) Augmentation of nociceptive reflexes and chronic deafferentation pain by chemical lesions of either dopaminergic terminals or midbrain dopaminergic neurons. Brain Res 751:1–12
33. Takeda R, Ikeda T, Tsuda F, Abe H, Hashiguchi H, Ishida Y, Nimishima T (2005) Unilateral lesions of mesostriatal dopaminergic pathway alters the withdrawal response of the rat hindpaw to mechanical stimulation. Neurosci Res 52:31–36
34. Millan MJ (2002) Descending control of pain.Prog Neurobiol 66:355–474
35. Meyer PJ, Morgan MM, Kozell LB, Ingram SL (2009) Contribution of dopamine receptors to periaqueductal gray-mediated antinociception. Psychopharmacology (Berl) 204:531–540
36. Chieng B, Christie MJ (2010) Somatostatin and nociceptin inhibit neurons in the central nucleus of amygdala that project to the periaqueductal grey. Neuropharmacology 59:425–430
37. Kirouac GJ, Li S, Mabrouk G (2004) GABAergic projection from the ventral tegmental area and substantia nigra to the periaqueductal gray region and the dorsal raphe nucleus. J Comp Neurol 469:170–184
38. Höftfelt T, Phillipson O, Goldman M (1979) Evidence for a dopaminergic pathway in the rat descending from the A11 cell group to the spinal cord. Acta Physiol Scand 107:393–395
39. Malmierca E, Martin YB, Nurse A (2012) Inhibitory control of nociceptive responses of trigeminal spinal nucleus cells by somatosensory corticalcufal projection in rat. Neuroscience 221:115–124